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ABSTRACT
Nuclear factor kappaB (NF-iB) plays an important
role in the transcriptional regulation of genes
involved in immunity and cell survival. We show
here in vitro and in vivo acetylation of RelA/p65 by
p300 on lysine 314 and 315, two novel acetylation
sites. Additionally, we confirmed the acetylation
on lysine 310 shown previously. Genetic comple-
mentation of RelA/p65/ cells with wild type and
non-acetylatable mutants of RelA/p65 (K314R and
K315R) revealed that neither shuttling, DNA binding
nor the induction of anti-apoptotic genes by tumor
necrosis factor a was affected by acetylation on
these residues. Microarray analysis of these cells
treated with TNFa identified specific sets of genes
differently regulated by wild type or acetylation-
deficient mutants of RelA/p65. Specific genes were
either stimulated or repressed by the acetylation-
deficient mutants when compared to RelA/p65 wild
type. These results support the hypothesis that site-
specific p300-mediated acetylation of RelA/p65
regulates the specificity of NF-iB dependent
gene expression.
INTRODUCTION
The inducible transcription factor family nuclear factor
kB (NF-kB) consists of dimeric proteins involved in many
diverse processes such as immune and stress responses and
the opposing processes of proliferation and apoptosis
(1–3). NF-kB is induced in almost all cell types by
diﬀerent extracellular stimuli causing the activation of an
enormous array of target genes (4). Thus, it is not
surprising that the speciﬁcity of NF-kB responses is very
important for the fate of a cell. It has been shown that
abnormal NF-kB activity, which is not always associated
with genetic alterations, plays a role in diﬀerent inﬂam-
matory diseases and cancer (5–7).
NF-kB speciﬁcity is regulated at diﬀerent levels in
the cell (8). One level of regulation is the selective
activation of distinct NF-kB complexes after induction
by diverse stimuli. In mammals there exist ﬁve family
members, c-Rel, RelB, p65 (RelA), p105/p50 (NF-kB1)
and p100/p52 (NF-kB2) that can form a range of homo-
and heterodimers (9). After regulated IkB (inhibitor of
NF-kB)-dependent NF-kB translocation to the nucleus,
these dimers bind with variable aﬃnities to consensus
NF-kB-binding sites in the promoter and enhancer regions
of their target genes, often cooperatively with other
transcription factors [e.g. IFNb promoter (10)]. This
integrates other signal transduction pathways with
the NF-kB pathway giving additional levels of speciﬁcity
and regulation to the transcriptional control of responsive
genes. The interaction with cell-type-speciﬁc co-factor
proteins has been shown to inﬂuence the transcriptional
potential of NF-kB (11). One of the co-factors of NF-kB
is the co-activator p300 and its homolog CBP (CREB-
binding protein). They have been shown to interact with
the RelA/p65 and the p50 subunit serving as molecular
bridges between NF-kB and the transcription machinery
(8,10,12–14). They contain intrinsic histone acetyltransfer-
ase activity catalyzing the acetylation of lysine residues
in histones and non-histone proteins (15,16). A growing
number of transcription factors are acetylated and
regulated by p300/CBP including p53 (17), GATA-1
(18), E2F-1 (19,20) and YY1 (21). Post-translational
acetylation inﬂuences diﬀerent properties of these
transcription factors such as DNA binding, protein–
protein interactions, protein stability and transcriptional
potential (22).
NF-kB is subject to a variety of post-translational
modiﬁcations [e.g. phosphorylation (23), ubiquitination
(24) or prolyl-isomerisation (25)] that modulate
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its activity. Phosphorylation of the RelA/p65 subunit by
the PKAc, MSK1 and PKC kinases enhances its
interaction with the co-activator p300/CBP and stimulates
the NF-kB transcriptional activity (26–28). In contrast,
ubiquitination of RelA/p65 on the promoter speciﬁcally
terminates the NF-kB response (24).
It has recently been shown that RelA/p65 and p50
are reversibly acetylated by p300 and PCAF (29–31).
Chen et al. identiﬁed lysine residues (K) 218, 221 and 310
of RelA/p65 as acceptor sites for p300 acetylation.
They reported that lysine 221 acetylation enhanced
DNA-binding activity of NF-kB in vitro and abolished
the interaction with IkBa leading to a prolonged NF-kB
response in the nucleus. The acetylation at lysine residue
310 was required for full transcriptional activity of RelA/
p65 (32). Kiernan et al. identiﬁed lysine 122 and 123 in
RelA/p65 as acetylation sites modiﬁed by both p300
and P/CAF. In contrast to K218, K221 and K310,
acetylation of K122 and K123 decreased the DNA
binding of RelA/p65 facilitating the removal of RelA/
p65 from the DNA and the export from the nucleus
by IkBa resulting in a faster termination of the NF-kB
response (30). Furthermore, a recent report presented
the TGF-b1 mediated acetylation of RelA/p65 at lysine
221 in vitro and in vivo enhancing the induced activation of
NF-kB by bacteria (33).
Together, these data question the precise functional
relevance of RelA/p65 post-translational acetylation
in NF-kB-dependent gene regulation in vivo. Thus, our
study aimed to identify the role of RelA/p65 acetylation
in vivo. We found that p300 eﬃciently acetylated RelA/p65
in vitro and in cells at lysine 314 and 315—two novel acetyl
acceptor sites. Additionally, our results conﬁrmed the
acetylation of RelA/p65 at the previously reported site
of lysine 310 in vitro and in vivo. We generated acetylation-
deﬁcient lysine to arginine substitution mutants of RelA/
p65 and stably complemented murine RelA/p65–/– cells
with these mutants. The nuclear-cytosolic shuttling and
the DNA binding of the acetylation-deﬁcient mutants
were similar to that of wild type RelA/p65. Furthermore,
induction of anti-apoptotic genes by TNFa was not
aﬀected by the non-acetylatable mutants of RelA/p65.
However, whole genome microarray analysis after TNFa
stimulation indicated that the expression of speciﬁc genes
was either positively or negatively aﬀected by the K/R
mutations. Our results imply that although general
transcriptional activity of RelA/p65 was not aﬀected by
acetylation at lysine 310, 314 and 315, the expression
of speciﬁc sets of genes was modulated by lysine-speciﬁc
acetylation of RelA/p65. Thus, site-speciﬁc acetylation
could serve as molecular mechanism to promote speciﬁcity
of NF-kB-dependent gene expression.
MATERIAL AND METHODS
Plasmids
hGCN5L, mP/CAF and hTip60 were cloned into
pFastBacHTb vector in frame with an N-terminal
6His-tag. pph-CMV-Km-RelA/p65 wild type was pre-
viously described in (13). pph-CMV-Km-RelA/p65K310R
(K310R), pph-CMV-Km-RelA/p65K314/K315R (K314/
315R) and pph-CMV-Km-RelA/p65K310R/K314/K315R
(KTR) were generated by site-directed mutagenesis
according to the QuickChange protocol (Stratagene)
using the following oligonucleotides:
K310R: 50CGTAAAAGGACATACGAGACCTTCA
GGAGCATCATGAAGAAGAGTCC30,
50GGACTCTTCTTCATGATGCTCCTGAAGGTCT
CGTATGTCCTTTTACG30,
K314/315R: 50CCTTCAGGAGCATCATGCGGAGG
AGTCCTTTCAGCGGACCC30,
50GGGTCCGCTGAAAGGACTCCTCCGCATGA
TGCTCCTGAAGG30 (bold letters represent K/R muta-
tion). pphCMV-Km-RelA/p65K122/123R, pphCMV-
Km-RelA/p65K218/221R, pphCMV-Km-RelA/p65K218/
221/310R were generated using the QuickChange site-
directed mutagenesis protocol with pph-CMV-Km-RelA/
p65 wild type as template vector. The speciﬁc primer
sequences can be received upon request. The combina-
torial mutant pphCMV-Km-RelA/p65K218/221/310/314/
315R (KQR) was generated with the same protocol
using pph-CMV-Km-RelA/p65K310R/K314/K315R as
template vector. All introduced mutations were
conﬁrmed by sequencing.
Reagents and antibodies
Mouse TNFa, Trichostatin A (TSA), Nicotinamide
(NAM), acetyl-Coenzyme A, calf thymus core histones
(H7755) and Trichloroacetic acid (TCA) were purchased
from Sigma. Sodium ﬂuoride (NaF) and beta-glyceropho-
sphate were purchased from Flucka. 14C-labeled acetyl
Coenzyme A (MC269) was obtained from Moravek
Biochemicals. Most of antibodies were from Santa Cruz
Biotechnology: anti-RelA/p65 (C-20, sc-372), anti-a-tubu-
lin (TU-02, sc-8035), control mouse IgG (sc-2025) and
anti-PCNA (PC10, sc-56). The anti-p300 monoclonal
antibody was purchased from BD Pharmingen (554215).
The anti-p50 antibody was a generous gift from N. Rice
(National Cancer Institute, Frederick, MD). Anti-myc
9E10 antibody was either puriﬁed from hybridoma cells
according to standard protocol or purchased from Roche
Applied Science. The polyclonal anti-acetylated-Lysine
antibody was from Cell Signaling. A speciﬁc antibody
against acetylated lysine 310 of RelA/p65 was generated in
collaboration with Abcam. The anti-Ccl-7 antibody was
purchased from Abcam (ab9911).
Tissue culture, cell transfections
Complemented RelA/p65–/– NIH 3T3 mouse embryonic
ﬁbroblasts (MEFs) and HEK 293T cells were maintained
in DMEM supplemented with 10% FCS, 100 units/ml
penicillin/streptomycin and non-essential amino acids
(GIBCO). Cells were transfected using the calcium
phosphate precipitation method.
Generation and purification of baculovirus expressed proteins
All recombinant proteins were expressed in Sf21 cells
using the Bac-To-Bac (GIBCO) or BacPAK (Clontech)
system. Recombinant His-tagged proteins were puriﬁed
over Ni2+-beads (ProBond, Invitrogen).
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In vitro acetylation assay
One microgram of recombinant human wild type
or mutant RelA/p65 was incubated with 0.5–1 mg recom-
binant p300 or CBP or equimolar amounts of hGCN5L,
mP/CAF or hTip60 in HAT buﬀer (50mM Tris–HCl pH
8.0, 100mM NaCl, 10% glycerol, 1mM DTT, 1mM
PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin, 1mM sodium butyrate) supplemented with
1.5 nmol 14C-acetyl CoA for 45min at 308C. Reactions
were stopped by adding 10Laemmli-buﬀer and proteins
resolved on SDS–PAGE with subsequent visualization
by Coomassie brilliant blue or SyproRuby staining.
The gel was immersed in 1M sodium salicylate for
20min at RT. After drying, the gel was exposed to
X-ray ﬁlms (Contatyp) at –808C.
MS/MS
In vitro acetylated RelA/p65 was resolved on SDS–PAGE,
ﬁxed and stained with Coomassie brilliant blue. The
corresponding protein band was then excised and washed
twice with 50% acetonitrile. After tryptic digestion the
protein sequence analysis was performed at the Harvard
Mass Spectrometry and Proteomics Resource Laboratory
by microcapillary reverse-phase HPLC nano-electrospray
tandem mass spectrometry (mLC/MS/MS) on a
ThermoFisher LCQ DECA XP quadrupole ion trap
mass spectrometer.
GST-pull down experiments
GST, GST-RelA/p65wt and GST-RelA/p65KTR proteins
were immobilized on glutathione beads (Amersham
Pharmacia) and incubated with puriﬁed his-p300 in
binding buﬀer (20mM Hepes pH 7.5, 60mM NaCl,
10% glycerol, 1.5mM MgCl2, 1mM DTT, 1mM PMSF
and 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin)
for 2 h at 48C rolling. Glutathione beads were washed
with binding buﬀer. Proteins were boiled, resolved on
SDS–PAGE and subjected to western blot analysis using
anti-his antibody (Qiagen).
Acetylation assay in cells
Myc-tagged RelA/p65 wild type, RelA/p65 acetylation-
deﬁcient mutants or control empty vector were
co-expressed with p300 in HEK 293T cells. After 15 h of
transfection, cells were treated with HDAC inhibitors
(HDACi: 2 mM TSA, 5mM NAM) alone or in combina-
tion with TNFa (30 ng/ml) for 30 or 45min, respectively.
Whole cell extracts were prepared (50mM Hepes pH 7.9,
420mM NaCl, 0.5% NP-40, 1mM PMSF, 0.5mM DTT,
1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin).
One milligram of whole cell extract and 2 mg of anti-myc
antibody were used for subsequent immunoprecipitation.
The immunocomplexes were analyzed by standard west-
ern blot analysis using anti-acetylated Lysine antibody.
Membranes were reprobed with anti-myc antibody.
Lentiviral complementation of RelA/p65–/–MEFs
Virus production and transduction of RelA/p65–/– MEFs
were performed as described in (34). Brieﬂy, HEK 293T
cells were transfected with 3.5mg of the envelope plasmid,
6.5mg of packaging plasmid, and 10 mg of pTV-myc-RelA/
p65 wild type, RelA/p65K/R mutants or the control pTV
vector. After 24 h the viral supernatant was harvested
and used to infect RelA/p65–/– MEFs. Thirty-six hours
post infection cells were split into selective medium
containing 2.5mg/ml Blasticidin (Sigma). Expression of
recombinant proteins in the complemented cells was
screened by western blot analysis. Pools of cells were
used for further analysis.
Electrophoretic mobility shift assay (EMSA)
Binding reactions were carried out in a total volume of
20 ml containing 10mM Tris–HCl pH 7.5, 50mM NaCl,
1mM DTT, 2mM PMSF, 0.25 mg poly dI-dC, 7% (v/v)
Ficoll/glycerol, 0.25 pmol HIV-LTR oligonucleotide
containing 2 kB binding sites labeled 50 with ATPg32P
and 7 mg of nuclear extract. The reaction was incubated
for 20min on ice and then resolved using a 5%
polyacrylamide gel in 0.5TBE. The gel was run at
150V for 3 h, dried and subjected to autoradiography.
When supershifts were performed the binding reaction
was pre-incubated with the indicated antibody for 20min
on ice before the labeled oligonucleotide was added.
Immunohistochemistry
Cells were plated at the density of 45 000 cells per cham-
ber on poly-L-lysine (Sigma)-coated chamber slides
(LAB-TEK) and incubated overnight at 378C and 5%
CO2. Next day the cells were treated with 30 ng/ml of
TNFa for the indicated time. The cells were ﬁxed in 4%
paraformaldehyde and then permeabilized with 0.2%
Triton-X-100/PBS. After blocking for 1 h in 2% BSA/
0.1% Triton-X-100/PBS slides were incubated with
anti-RelA/p65C-20 antibody (1:300 dilution) followed
by anti-rabbit Cy3 antibody (1:250 dilution, Jackson
Immunology). The samples were washed and Vectashield
mounting solution (Vector laboratories) was applied to
prevent bleaching. Cells were visualized using an Olympus
T50 microscope.
Whole cell extract preparation and immunoprecipitation
for RelA/p65-p300 interaction
The complemented cell lines were treated with TNFa
(30 ng/ml) for 30min. Whole cell extracts were prepared
(25mM Hepes pH 7.9, 300mM KAc, 1% NP-40, 1mM
PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin, 50mM NaF, 20mM beta-glycerophosphate).
One milligram of whole cell extract was incubated with
2 mg of anti-p300 antibody or control IgG antibody for
2.5 h at 48C. The immunocomplexes were analyzed
by standard western blot analysis using anti-RelA/p65,
anti-p300 and anti-tubulin antibodies.
Nuclear extract preparation and immunoprecipitation
for in vivo acetylation of K310
Nuclear extracts were prepared as previously described in
(35). Two hundred micrograms of TNFa (30 ng/ml) and
HDAC inhibitor [TSA (2 mM), NAM (5mM)] treated
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nuclear extracts of complemented cells were incubated
with 2 mg of anti-RelA/p65C-20 antibody for 2.5 h at 48C
rolling in binding buﬀer (20mM Hepes pH 7.9, 80mM
NaCl, 2.5mM MgCl2, 0.05% NP-40, 1mM PMSF, 1 mg/
ml pepstatin, 1 mg/ml bestatin, 1 mg/ml leupeptin). After
incubation with protein G-sepharose beads (Amersham
Pharmacia) for another hour, the immunocomplexes
were extensively washed in washing buﬀer (20mM
Hepes pH 7.9, 100mM NaCl, 2.5mM MgCl2, 0.05%
NP-40, 1mM PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin,
1 mg/ml leupeptin). Proteins were boiled, resolved on
SDS–PAGE and analyzed by western blot using the
anti-RelA/p65ac310 antibody. Membranes were reprobed
with anti-RelA/p65 antibody.
Cell survival assay
The complemented cells (pTV empty vector control, RelA/
p65wt, RelA/p65K310R, RelA/p65K314/315R and RelA/
p65KTR) were plated in 12-well dishes at a density of
90 000 cells/ml. After 24 h of incubation, cells were starved
overnight with 0% FCS containing medium and then
treated with TNFa (30 ng/ml) or left untreated for
additional 10 h. The surviving cells were counted using
Trypan blue. The ratios of TNFa-treated and untreated
cells were calculated for each cell line. Each condition was
carried out in duplicate. A representative assay of three
independent experiments is shown.
RNA preparation
Total RNA was isolated three independent times from
TNFa-treated lysates from the diﬀerent complemented
RelA/p65–/– MEFs with the ‘Total RNA isolation kit’
(Agilent Technologies). RNA quality was assessed with
the RNA 6000 Nano kit using the Bioanalyzer 2001
(Agilent Technologies). Puriﬁed RNAs were converted
into double-stranded cDNA and transcribed into Cy3-/
Cy5 (PerkinElmer/NEN Life Science)—labeled cRNA
using the ‘Low RNA Input Linear Amp Kit’ (Agilent
Technologies). cRNA from wild type RelA/p65 cells
was Cy5-labeled while the RelA/p65K/R mutant cRNAs
were Cy3-labeled. The puriﬁcation of the labeled cRNAs
was performed with the RNeasy kit (Qiagen). Dye
incorporation was measured on the ND-1000
Spectrophotometer (NanoDrop Technologies)
Gene expression profiling
Gene expression proﬁling was performed in the Func-
tional Genomics Center Zurich using the two-colour
Agilent Microarray system (Agilent Technologies). 1 mg
of fragmented Cy5-labeled wild type and 1 mg of
Cy3-labeled mutant cRNA were each co-hybridized on
the Whole Mouse genome 60mer-oligo array (G4122A,
Agilent Technologies) according to manufacturers
protocol. The microarray analysis was performed in
triplicates. Slides were scanned using the Agilent DNA
microarray scanner and the scans were quantiﬁed with the
Agilent Feature Extraction software.
Data analysis
Data analysis was performed with GeneSpring software
(Silicon Genetics). For the statistical comparisons of the
RelA/p65 mutants and RelA/p65 wild type we only
considered genes that were present in either the mutant
or the wild type. We declared a gene as present in a
comparison, if the hybridisation intensity was in all
mutant replicates or in all wild type replicates above
200. Student’s t-test was used to compute the signiﬁcance
of diﬀerential expression and 0.01 was used as signiﬁcance
threshold. For each list of signiﬁcant genes, the
Benjamini–Hochberg false discovery rate was computed
and is reported in the results section. Furthermore,
genes were ﬁltered according to their fold change and
only genes exceeding a fold change of 1.5 up or down
are reported.
Quantitative real time RT-PCR
Total RNA from untreated or 45min TNFa-treated
cell lines (pTV, RelA/p65wt, RelA/p65K310R, RelA/
p65K314/315R and RelA/p65KTR) was reverse tran-
scribed using the high capacity cDNA Archive kit
according to manufacturers protocol (ABI). Real-time
PCR was performed using mouse-speciﬁc TaqMan probes
(Gene expression assays, ABI) for Ccl-7, Iﬁ-44, Ccl-20 and
Gpb-2. TaqMan probes for 18SrRNA and Rps6
were used to normalize for diﬀerences in RNA input.
Rotor-Gene3000A (Corbett) was used to perform the
real-time PCR reactions and the REST program was
applied for analysis (36). The ﬁgures show the averaged
results of three independent experiments.
TCA protein precipitation and Ccl-7 protein detection
Complemented cells (RelA/p65wt, RelA/p65K310R,
RelA/p65K314/315R and RelA/p65KTR) were starved
with 0% FCS containing medium for 1.5 h and then
treated with TNFa (30 ng/ml) or left untreated. After 4 h
of TNFa treatment, the medium was collected and 250 ng
of recombinant PCNA was added as a control for the
TCA protein precipitation. The medium was incubated
overnight at 48C with one-fourth volume of TCA (100%
w/v) and centrifuged. Pellets were washed twice with
acetone and lysed with lysis buﬀer (50mM Hepes pH 7.5,
420mM NaCl, 2mM EDTA, 0.5% NP-40, 15% glycerol,
1mM PMSF, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin). Forty micrograms of proteins were analyzed
by standard western blot analysis using anti-Ccl-7 and
anti-PCNA antibodies.
RESULTS
RelA/p65 is acetylated in vitro by p300 or CBP
Since RelA/p65 was reported to interact directly with
several histone acetyltransferases (HAT), we investigated
whether RelA/p65 could serve as a substrate in an in vitro
acetylation assay. We compared the ability of diﬀerent
HATs to acetylate RelA/p65 in vitro. Full-length RelA/
p65 was incubated with recombinant p300, CBP, GCN5L,
P/CAF or Tip60 (all proteins expressed and puriﬁed from
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insect cells, Figure 1A) in the presence of radioactively
labeled acetyl-coenzyme A (acetyl-CoA) as a donor of the
acetyl group (Figure 1B). All tested HATs, except for
Tip60, acetylated RelA/p65 in vitro (Figure 1B). Calf
thymus core histones were used as a positive control of
acetylation (Figure 1C). p300 and CBP were the most
potent HATs for RelA/p65 in our system. This prompted
us to focus on p300 in this study.
RelA/p65 is acetylated in vitro by p300 or CBP
at lysine 310, 314 and 315
To identify the acetylation residues, in vitro acetylated
RelA/p65 by p300 was digested with trypsin and the
resulting peptides were analyzed by LC/MS/MS. 81.8% of
the K310 comprising peptides contained an acetylated
K310. 61.9% of K314 and 56.52% of K315 containing
peptides showed acetylated K314 and acetylated K315,
respectively. These data indicate that lysine 310, 314 and
315 were acetylated by p300. The identiﬁed lysine residues
are located close to the C-terminus of the Rel homology
domain (RHD) (Figure 2A). To conﬁrm these ﬁndings,
the corresponding lysines were replaced with arginine
residues by site-directed mutagenesis. Substitution of
lysine to arginine maintains the positive charge of the
residue and may cause only minimal changes in the
local environment of the protein. Wild type or mutated
RelA/p65 harboring K310R, K314/315R or all three
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Figure 1. RelA/p65 is acetylated by p300 and CBP in vitro. (A) Recombinant histone acetyltransferases (HATs) expressed and puriﬁed from
insect cells were analyzed by SDS–PAGE and Coomassie staining. Molecular weight markers are shown on the left. (B) In vitro acetylation
assay using full-length RelA/p65 and indicated HATs. RelA/p65 was incubated in the presence of radioactively labeled [14C]-acetyl-CoA with 500 ng
of p300 or CBP or the equimolar amount of GCN5L, P/CAF or Tip60. Proteins were resolved on SDS–PAGE, stained with SyproRuby (left)
and exposed to X-ray ﬁlms (right). RelA/p65 acetylation signals are indicated with an arrow. HATs or HAT autoacetylation signals are
indicated with an asterisk (). (C) In vitro acetylation of histones. In vitro acetylation assay was performed as described in (B).
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K310/314/315R (KTR) substitutions were expressed and
puriﬁed from insect cells (Figure 2B). Subsequently,
all proteins were subjected to in vitro acetylation by
p300 or CBP (Figure 2C and Supplementary Figure 1).
Acetylation of RelA/p65 mutated at single K310 or
K314/315 was only slightly reduced compared to wild
type, while mutation of all three lysine residues abolished
acetylation of RelA/p65 (Figure 2C). When the puriﬁed
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protein substrates were tested only in the presence of
acetyl-CoA, no acetylation was observed conﬁrming that
the acetylation was mediated by p300 and not by a
co-puriﬁed acetyltransferase. These results clearly indicate
that K310, K314 and K315 of RelA/p65 are the main
acetylation sites of p300 in vitro. To conﬁrm that the
RelA/p65KTR mutant was still able to interact with
p300, GST-pull down experiments were performed using
GST-RelA/p65 wild type or GST-RelA/p65KTR as bait
proteins in the presence of puriﬁed p300. Subsequent
western blot analysis revealed that p300 was able to
equally directly interact with both RelA/p65 wild type and
the RelA/p65KTR mutant (Figure 2D). These results
indicate that abolished acetylation of the RelA/p65KTR
mutant was due to the lack of speciﬁc sites and not due to
the inability of this mutant to interact with p300.
Lysine 314 and 315 of RelA/p65 are acetylated
by p300 in cells
To examine if lysine residues 314 and 315 of RelA/p65
are acetylated in cells, myc-tagged wild type RelA/p65,
RelA/p65 acetylation-deﬁcient mutants (RelA/p65K310R,
RelA/p65K314/315R, RelA/p65KTR) or myc-tagged
empty control vector were ectopically expressed in
HEK 293T cells together with the histone acetyltransfe-
rase p300. Previous experiments had revealed that over-
expressed RelA/p65 wild type can only be detected as
acetylated in the presence of ectopically expressed p300
[(29) and data not shown]. TNFa was applied to induce
NF-kB, while HDAC inhibitors (HDACi: TSA and
NAM) were used to inhibit histone deacetylases.
Subsequent immunoprecipitation analysis with anti-myc
antibody and western blot analysis using anti-acetylated
Lysine antibody revealed acetylation of RelA/p65 wild
type (Figure 3A). The acetylation of wild type RelA/p65
was already close to saturation before TNFa stimulation
most probably due to the activation of the NF-kB
pathway through overexpression of RelA/p65. However,
an increase of acetylation after TNFa stimulation is
detected in the RelA/p65K310R mutant, strongly suggest-
ing that lysine 314 and 315 are acetylated upon TNFa
induction. A signiﬁcant decrease in acetylation was
detected in the RelA/p65 acetylation-deﬁcient double
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Figure 3. RelA/p65 is acetylated in cells on lysine 314 and 315 by p300. (A) Wild type myc-RelA/p65 and myc-RelA/p65K/R mutants were
immunoprecipitated with anti-myc antibody from HDACi (TSA/NAM) and –/+ TNFa treated HEK 293T cells transfected with either empty
control vector or diﬀerent CMV-myc-RelA/p65 vectors (wt, K310R, K314/315R or KTR) along with CMV-p300. Western blot analysis of the
immunocomplexes was performed after SDS–PAGE using anti-acetylated Lysine antibody (right panel). 2% input lanes are shown in the left panel.
The membranes were reprobed with anti-myc antibody to assess equal input and immunoprecipitation. (B) HEK 293T cells were transfected with
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mutant (K314/315R). A small residual amount of
acetylation was still detected when the triple mutant
(KTR) of RelA/p65 was expressed in HEK 293T cells
indicating that also other lysine residues are acetylated by
p300 (Figure 3A).
To investigate if one of the previously reported sites
[K122, K123 (30) and K218, K221 and K310 (32)] is
acetylated in our system a variety of acetylation-deﬁcient
point mutants of RelA/p65 were generated: RelA/
p65K122/123R, RelA/p65K218/221R, RelA/p65K218/
221/310R and a combinatorial mutant RelA/p65K218/
221/310/314/315R (RelA/p65KQR) harboring the acet-
ylation acceptor sites identiﬁed in this study and the
sites identiﬁed by Chen et al. after TNFa stimulation (32).
The diﬀerent mutants of RelA/p65 were expressed in HEK
293T cells along with p300 in the presence of TNFa and
HDAC inhibitors. Anti-myc immunoprecipitation and
anti-acetylated Lysine western blot analysis revealed a
slight decrease in acetylation of the RelA/p65K122/123R
and RelA/p65K218/221R mutant when compared to wild
type RelA/p65 (Figure 3B). However, RelA/p65K218/221/
310R showed a higher reduction in acetylation while the
RelA/p65KQR mutant showed a decrease in acetylation
of 90% (when compared to the wild type) indicating that
K314 and K315 greatly contribute to the detected p300-
dependent acetylation level in RelA/p65 after TNFa
treatment. It also points out that K218 and K221 might
probably be the other lysine residues acetylated in cells by
p300 (Figure 3A). Together, these data indicate that RelA/
p65 is acetylated in cells mainly on lysine 314 and 315 by
p300.
Endogenous RelA/p65 is acetylated in vivo in TNFa
stimulated cells
To investigate the role of RelA/p65 acetylation of K310,
K314 and K315 in vivo, RelA/p65–/– NIH 3T3 mouse
embryonic ﬁbroblasts (MEF) were genetically comple-
mented using lentiviruses encoding myc-RelA/p65 wild
type, myc-RelA/p65K310R, myc-RelA/p65K314/315R or
myc-RelA/p65KTR. After appropriate selection cells were
kept in pools and the expression of recombinant proteins
was analyzed by western blotting using an anti-RelA/p65
antibody (Figure 4A). The cells transduced with control
virus encoding the resistance gene [mock infected (pTV)]
and non-transduced wild type NIH 3T3 cells expressing
endogenous RelA/p65 protein were included as controls.
The expression levels of the recombinant wild type
and mutated RelA/p65 proteins were comparable to
that observed for endogenous RelA/p65 in NIH 3T3
cells. Furthermore, cell growth analysis revealed that
the proliferation rate was comparable between the tested
cell pools under normal growth conditions (data
not shown).
We and others showed that RelA/p65 is acetylated in
cells in a TNFa-dependent manner [Figure 3A and (29)].
In order to investigate whether endogenous RelA/p65
is acetylated at the identiﬁed lysine residues in vivo,
antibodies directed against RelA/p65 peptides acetylated
at residues 310, 314 or 315 were generated. Nuclear
extracts were prepared after treating the complemented
cells with TNFa and HDAC inhibitors (TSA and NAM).
Upon TNFa treatment RelA/p65 nuclear import was
induced in RelA/p65wt and RelA/p65 mutant comple-
mented cells (Figure 4B). Immunoprecipitation with an
anti-RelA/p65 antibody and subsequent western blot
analysis using the speciﬁc acetyl K310 antibody revealed
that RelA/p65 was indeed acetylated at this site upon
TNFa treatment (Figure 4C, left panel). TNFa induced
acetylation of RelA/p65 was further conﬁrmed by
immunoprecipitating RelA/p65 from untreated and
TNFa stimulated cells (Figure 4C, right panel).
Acetylated RelA/p65 could only be detected in the extracts
stimulated by TNFa. Acetylation of RelA/p65 could not
be detected in the input lanes due to low detection
sensitivity of the anti-acetyl 310 antibody. Antibodies
raised against acetylated 314 and acetylated 315 were
found to be unspeciﬁc in this analysis (data not shown).
To investigate if the abolished acetylation of RelA/
p65K310R and RelA/p65KTR was due to their inability
to interact with endogenous histone acetyltransferase
p300, immunoprecipitation analyses with the diﬀerent
mutants and p300 were performed. Whole cell extracts
were prepared from wild type and mutant RelA/p65
complemented cell lines after TNFa stimulation to induce
NF-kB. Immunoprecipitation with either anti-p300 or
control IgG antibody and subsequent western blot
analysis using anti-RelA/p65 antibody revealed that
endogenous RelA/p65K10R, RelA/p65K314/315R and
RelA/p65KTR are able to interact with endogenous
p300 upon TNFa stimulation to the same extend as wild
type RelA/p65 (Figure 4D).
K314/315R substitution mutation does not affect the
shuttling, the DNA-binding ability or the protection
against TNFa-induced cell death of RelA/p65
The complemented cells were treated with TNFa and
subcellular localization of the recombinant RelA/p65
proteins was analyzed by immunoﬂuorescence analysis
at diﬀerent time points (Figure 5A). Nuclear translocation
of the recombinant RelA/p65 wild type was detected
after 20min of TNFa treatment and relocation to the
cytoplasm after 60min. A similar shuttling kinetics was
observed for endogenous RelA/p65 protein in NIH 3T3
cells (data not shown). Analysis of the cells complemented
either with K310R, K314/315R or KTR revealed no
signiﬁcant diﬀerences in the shuttling kinetics between
mutated RelA/p65 and RelA/p65 wild type proteins
(Figure 5A). This suggested that acetylation of RelA/
p65 at the three tested lysine residues was not essential for
the regulation of the RelA/p65 nuclear-cytoplasmic
redistribution. This observation is supported by our
ﬁndings that IkBa was able to bind to RelA/p65 wild
type and the acetylation-deﬁcient mutants with similar
aﬃnity (data not shown).
Next we investigated the inﬂuence of p300-mediated
RelA/p65 acetylation on the ability of RelA/p65 to bind
DNA. Nuclear extracts of the complemented cells treated
with TNFa were tested in an electro mobility shift assay
using an oligonucleotide containing two kB elements of
the HIV-LTR promoter. The experiments revealed that
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mutations of K310, K314 and K315 did not signiﬁcantly
inﬂuence the TNFa-induced DNA binding of RelA/p65
(Figure 5B). Binding was substantially reduced by
competition with non-labeled oligonucleotides containing
a wild type kB site, but not a mutated kB site, indicating
that the binding was speciﬁc (data not shown).
The presence of RelA/p65 and p50 in the complex was
conﬁrmed by supershift experiments using speciﬁc
anti-RelA/p65 and anti-p50 antibodies, respectively
(Figure 5B). Together, these ﬁndings show that the
acetylation-deﬁcient mutants are able to translocate
to the nucleus and bind to DNA to the same extent as
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Figure 5. Mutation of the acetylation sites in RelA/p65 does not aﬀect its nuclear translocation and DNA binding. (A) The complemented cells were
treated with TNFa and ﬁxed with paraformaldehyde followed by immunostaining using anti-RelA/p65 antibodies. Subcellular localization of RelA/
p65 protein was analyzed by immunoﬂuorescence microscopy. (B) Electro mobility shift assays were performed with nuclear extracts from the
untreated or TNFa treated cells using 32P-labeled oligonucleotide DNA containing 2kB sites. The bound complexes were characterized by anti-RelA/
p65 or anti-p50 supershift assays. Speciﬁc NF-kB complexes are indicated with an arrow, unspeciﬁc bands are marked with an asterisk (). (C) Cell
viability assay after TNFa treatment. The diﬀerent complemented cell lines (pTV, RelA/p65wt, K310R, K314/315R and KTR) were starved for 14 h
with 0% FCS medium and then left untreated or treated with TNFa (30 ng/ml) for 10 h. The number of surviving cells (%) after TNFa treatment
was calculated as described in ‘Material and methods’ section.
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RelA/p65 wild type. These results are in accordance with
previously published data where K310 mutation to
arginine did not aﬀect subcellular localization, DNA
binding or interaction with IkBa (32).
The deletion of the RelA/p65 gene in mouse cells is
known to render them vulnerable to TNFa-induced cell
death, stressing the important role of RelA/p65 in cell
survival (37). To investigate whether TNFa-induced
acetylation of RelA/p65 would aﬀect the protective
function of RelA/p65, cell viability assays were performed.
The control cell line pTV (RelA/p65–/– cells comple-
mented with empty vector), RelA/p65 wild type and the
three diﬀerent acetylation-deﬁcient RelA/p65 mutant cell
lines were either left untreated or were stimulated with
TNFa for 10 h. The number of surviving cells after
treatment was determined using Trypan blue and com-
pared to the number of untreated cells (Figure 5C). As
expected, the pTV cells were not protected from TNFa-
induced cell death due to their lack of RelA/p65.
However, the non-acetylatable mutants of RelA/p65
(K310R, K314/315R and KTR) protected the cells from
cell death to the same extend as RelA/p65 wild type,
indicating that the acetylation of RelA/p65 at the three
mutated lysines does not aﬀect substantially the tested
pathway or that a possible eﬀect could be compensated by
the expression of RelA/p65-independent genes.
Determination of genes regulated by p300-mediated
acetylation of RelA/p65 on lysine 314 and 315
To investigate the functional relevance of lysine 314 and
315 acetylation, microarray analyses were performed
using the Agilent Whole Mouse Genome Array.
The complemented cell lines (RelA/p65 wild type, RelA/
p65K310R, RelA/p65K314/315R and RelA/p65KTR)
were treated for 45min with TNFa to induce NF-kB
and total RNA was isolated in three independent
replicates from these cells. RT-PCR for known TNFa-
dependent NF-kB target genes was performed to check
whether the TNFa induction was successful. The IkBa
mRNA was induced to the same extend in the wild type
and acetylation-deﬁcient mutant cell lines (data not
shown). RNA was ampliﬁed and labeled. The RNA
from the diﬀerent mutants (K310R, K314/315R and
KTR) was then each co-hybridized with wild type RNA
(RelA/p65 wild type cells) to the two-color whole
mouse genome array. Statistical analysis of the TNFa-
induced expression proﬁles aimed at identifying diﬀeren-
tially regulated genes when comparing the diﬀerent
mutant cell lines with the wild type cell line. After
performing this comparison, we identiﬁed following
numbers of potentially regulated genes for K310R RelA/
p65 versus wild type RelA/p65: 1149 signiﬁcantly
regulated genes with a P value 0.01 and a signal intensity
> 200 at a false discovery rate of 18.61%. Thereof 79 genes
were upregulated more than 1.5 times and 82 down-
regulated more then 1.5 times at a P value  0.01
(Supplementary Table S1). In the K314/315R RelA/p65
versus wild type RelA/p65 comparison we found 735
potentially regulated genes at P 0.01 (signal intensity
>200 and false discovery rate 28.43%). Ninety-seven
genes were found to be upregulated with a fold change
>1.5 and 54 downregulated with a fold change of <0.67
(P 0.01) (Supplementary Table S2). When we ﬁnally
analyzed the KTR mutant we found 1233 genes signiﬁ-
cantly regulated with a signal >200 and P 0.01 at a false
discovery rate of 17% (i.e. 216 false positives). Of these
1233 regulated genes 150 were upregulated with a fold
change >1.5 and 116 downregulated with a fold change
<0.67 (P 0.01) when compared to wild type RelA/p65
(Supplementary Table S3). To investigate if common
regulated genes were present in the diﬀerent cell lines
the overlap of the signiﬁcantly downregulated and
upregulated genes was generated at a P value 0.01
(Figures 6A and 7A). The overlap of genes between the
diﬀerent RelA/p65 mutants was small, possibly indicating
distinct sets of genes being regulated by the diﬀerent
mutants.
To validate the results derived from the microarray
studies, and to conﬁrm the p65 dependency and TNFa
induction of the analyzed genes, we performed quantita-
tive RT-PCR for some selected genes. The following genes
were chosen from the lists of overlapping diﬀerentially
regulated genes at P value 0.01: Ccl-20, Ccl-7, Iﬁ-44 and
Gbp-2. To perform quantitative real-time RT-PCR, RelA/
p65–/– cells complemented either with the empty vector
pTV, RelA/p65 wild type, RelA/p65K310R, RelA/
p65K314/315R or RelA/p65KTR mutant were left
untreated or were stimulated with TNFa for 45min.
Total RNA was isolated and reverse transcribed with
random hexamer primers to obtain cDNA. Gene expres-
sion of Ccl-20, Iﬁ-44 and Gbp-2 was highly dependent on
the acetylation of RelA/p65 at the identiﬁed sites, since
only low levels of expression of these genes could
be detected in cells expressing any of the mutants
(Figure 6B–D, right panel, black bars). On the other
hand, Ccl-7 expression was increased in cells expressing
the K314/315R (2-fold) and the KTR mutant (2.59-fold)
(Figure 7B, right panel). In the present analysis, the
expression proﬁles obtained by microarray analysis
were conﬁrmed by quantitative RT-PCR analysis for all
tested genes. However, the two methods showed higher
correlation in the upregulated gene (Ccl-7; Figure 7B)
than in the downregulated genes (Ccl-20, Iﬁ-44 and
Gbp-2; Figure 6B–D).
In order to examine if these selected genes require RelA/
p65 to be induced upon TNFa treatment, we compared
their expression levels in the wild type cell line and in the
control cell line pTV upon TNFa treatment. The four
genes were upregulated in wild type cells, indicating that
they were RelA/p65-dependent (left panels in Figures 6B–
D and 7B). To determine the induction of these selected
genes after TNFa stimulation in the diﬀerent complemen-
ted cell lines, expression levels upon TNFa treatment were
compared with unstimulated samples. All four genes were
induced upon TNFa stimulation in wild type cells (middle
panels from Figures 6B–D and 7B). However, among the
downregulated genes, only Ccl-20 was stimulated after
TNFa treatment in all acetylation-deﬁcient mutants,
though to a reduced amount than in the wild type cell
line (Figure 6B–D). This suggests that gene expression of
Ccl-20, Iﬁ-44 and Gbp-2 can only be properly induced by
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Figure 6. Acetylation of RelA/p65 at lysine 310, 314 and 315 activates gene speciﬁc transcription. (A) Venn diagram showing the numbers of
common down regulated genes between the signiﬁcantly regulated genes in the diﬀerent RelA/p65 acetylation-deﬁcient cell lines compared to the wild
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TNFa when RelA/p65 is acetylatable by harboring lysines
at the position 310, 314 or 315. The Ccl-7 gene was induced
by TNFa in all cell lines (Figure 7B, middle panel).
To demonstrate that transcriptional changes in gene
expression correlate with changes in corresponding
protein expression, western blot analysis was performed
for Ccl-7 in the complemented cell lines. Upregulation of
Ccl-7 protein was detected in the RelA/p65 acetylation-
deﬁcient mutant cell lines compared to wild type after 4 h
of TNFa stimulation (Figure 7C).
Taken together, the results obtained in the microarray
analysis could be conﬁrmed by the complementary real
time RT-PCR method for four selected genes.
Interestingly, Ccl-7 protein expression analysis in the
distinct acetylation-deﬁcient cell lines indicated that the
diﬀerential gene regulation detected in the microarray
analysis is indeed translated into protein expression.
Additionally, this analysis provides strong evidence that
acetylation of RelA/p65 at lysines 310, 314 and 315
positively or negatively regulates the transcription of
speciﬁc genes.
DISCUSSION
Increasing experimental evidence has indicated that
NF-kB-dependent gene expression is regulated by diﬀer-
ent post-translational modiﬁcations including acetylation
(38,39). The acetylation-dependent NF-kB regulation
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Figure 7. Acetylation of lysine 314 and 315 downregulates gene and protein expression. (A) Venn diagram of diﬀerentially upregulated genes found
in the microarray analysis when the diﬀerent RelA/p65 acetylation-deﬁcient cell lines were compared to the wild type cell line. (B) Quantitative real-
time RT-PCR validation for Ccl-7. The expression in the wild type cell line relative to pTV cell line in the presence of TNFa is shown in the left
panel. The TNFa induction of this gene in the diﬀerent cell lines is shown in the middle panel. The comparison between the microarray (white bars)
and the real-time PCR (black bars) experiment is shown on the right side. The mean values from three independent, normalized measurements are
shown with standard deviations. (C) Diﬀerential expression of Ccl-7 protein in acetylation-deﬁcient cell lines of RelA/p65. Proteins present in the
medium of complemented cells treated with TNFa for 4 h or left untreated were precipitated using TCA. Total 250 ng of recombinant PCNA was
added as control to the collected medium before the precipitation was carried out. Western blot analysis was performed using anti-Ccl-7 and anti-
PCNA antibodies. Total 250 ng of recombinant PCNA were loaded on the last lane of the SDS–PAGE to control the protein precipitation.
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was shown to occur via many diﬀerent mechanisms (40).
For example acetylation of histones is known to
regulate NF-kB-dependent gene accessibility for the
transcriptional machinery (38). The direct acetylation of
NF-kB was reported to regulate the transcriptional
potential of NF-kB, the duration of the NF-kB response,
its DNA-binding activity as well as protein–protein
interactions with several transcription cofactors
(32,41,42).
In this study we have addressed the role of p300-
mediated acetylation of RelA/p65 in the regulation of gene
expression in vivo. We identiﬁed three lysines (K310, K314
and K315) in RelA/p65 as targets for the acetylation by
p300 in vitro and in cells upon TNFa stimulation
(Figures 2A and 3A). Interestingly, lysine 310 was
previously shown to be acetylated by p300 (32).
However, we additionally found two novel lysine residues,
lysine 314 and 315, acetylated in RelA/p65 not reported
before. It is important to mention that among the
previously reported acetylation sites by Kiernan et al.
and Chen et al. (30,32), we could only conﬁrm the
acetylation of K310 in our experimental system
(Figure 3B). This could be due to the diﬀerent experi-
mental procedures; stimuli (TNFa versus PMA) and cell
lines (HEK 293T cells versus Jurkat T cells) used in the
studies and could point towards a very speciﬁc stimulus
and cell-type-dependent regulation of RelA/p65 through
acetylation. However, our results suggest additional yet to
be identiﬁed p300 speciﬁc acetylation sites in RelA/p65
other than lysine 218, 221, 310, 314 and 315 (Figure 3C).
The relevance of the in vitro acetylation sites identiﬁed in
our study was conﬁrmed by the ability of endogenous
RelA/p65 to be acetylated in vivo upon TNFa stimulation
using an acetylation site-speciﬁc antibody (Figure 4C).
To investigate the role of RelA/p65 acetylation in cells
we genetically complemented RelA/p65–/– ﬁbroblasts
with a control vector (pTV) or cDNAs encoding for
RelA/p65 wild type, K310R, K314/315R and KTR
mutant (Figure 4A). Analysis of the complemented cells
revealed that the mutation of the acetylation sites did not
aﬀect the kinetics of the cytoplasmic-nuclear redistribu-
tion of RelA/p65 upon TNFa stimulation (Figure 5A).
This implied that the upstream signalling events are not
regulated by the acetylation of RelA/p65 at the identiﬁed
sites. Furthermore, cell survival assays were performed to
examine whether the acetylation of RelA/p65 is involved
in the protection from TNFa-induced cell death. No
diﬀerence was seen in cell survival when RelA/p65–/– cells
complemented with wild type RelA/p65 were compared to
cells complemented with the acetylation-deﬁcient mutants,
indicating that the acetylation of RelA/p65 on lysine 314
and 315 is not involved in the TNFa-dependent cell death
pathway (Figure 5C).
In order to elucidate the inﬂuence of RelA/p65
acetylation on gene expression in vivo we performed
genome-wide microarray analyses using total RNA
isolated from the complemented cells after TNFa stimula-
tion. We identiﬁed subsets of genes, which were speciﬁ-
cally modulated depending on the ability of RelA/p65 to
be acetylated at lysine 310, 314 or 315 (Supplementary
Tables 1–3). The number of common signiﬁcantly down
or upregulated genes found in the current analysis of the
diﬀerent cell lines is small, indicating that acetylation of
RelA/p65 at lysine 310, 314 and 315 is possibly modulat-
ing the expression of only a subset of genes (Figures 6A
and 7A). Four genes from the distinct subsets of
diﬀerentially expressed genes were selected for validation:
Iﬁ-44, Ccl-20 (Mip-3a), Gbp-2 and Ccl-7 (MCP-3);
thereof Ccl-20 is a known NF-kB target gene (43).
Iﬁ-44, Ccl-20 and Gbp-2 gene expression showed to be
dependent on acetylation of RelA/p65 at lysine 310, 314
and 315. Expression of Ccl-7 was found to be repressed by
acetylated RelA/p65. This was supported by the protein
analysis performed for Ccl-7, which revealed induction of
Ccl-7 protein expression in the acetylation-deﬁcient
mutant cell lines (Figure 7C). The increase in Ccl-7
protein only slightly correlated with the increase of
mRNA levels detected in the diﬀerent mutants at 45min
of TNFa stimulation (compare Figure 7B, right panel).
This could be explained by the diﬀerences in stimulation
duration for mRNA (45min) and protein (4 h) detection
and by additional regulatory mechanisms (such as
secretion), which might inﬂuence the quantity of proteins.
When the induction of gene expression upon TNFa
stimulation was investigated, diﬀerences were detected
between the four genes. From the selected genes, the
chemokines Ccl-20 and Ccl-7 were the only genes induced
by TNFa in the mutant cell lines. Even though the
upstream events of TNFa-induced NF-kB signalling were
shown to be normal in our study, Iﬁ-44 and Gbp-2
gene expression was not induced by TNFa in the K/R
mutant cell lines suggesting that regulation by K310, 314
and 315 acetylation is essential for the ﬁrst group of genes
(Iﬁ-44, Gbp-2) and required for the latter group (Ccl-20
and Ccl-7).
The results of the microarray analysis and the
quantitative real-time PCR revealed that the acetylation
of RelA/p65 does not always correlate with activation of
gene expression as has been suggested before (32). Rather,
we provide evidence that the p300-mediated acetylation of
RelA/p65 contributes to both gene-speciﬁc activation and
repression of transcription. It is unknown how RelA/p65
acetylation signals to activate certain genes while simulta-
neously suppressing the expression of others. One
hypothesis would be that the regulation of certain genes
by p300-mediated acetylation of RelA/p65 promotes the
recruitment of additional factors or stabilizes the forma-
tion of speciﬁc pre-initiation complexes at promoter sites.
Like this, acetylated RelA/p65 could serve as a factor that
regulates the recruitment of these proteins. It has been
previously reported that many proteins can speciﬁcally
recognize and bind acetylated lysine residues in histones
and transcription factors through their bromo domains
(44–46). Among them are well-characterized histone
acetyltransferases (e.g. p300, P/CAF and GCN5) (47),
subunits of chromatin remodelling complexes (e.g.
ATPases of SWI2/SNF2 and proteins of the WAL/BAZ
family of ISWI-associated proteins) (48) and a general
cofactor of the basal transcription machinery, TAF1 (49).
The nature of the recruited co-activator/co-repressor
would determine the response of the speciﬁc genes.
Another hypothesis would be that the presence of other
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cis-regulatory elements in a targeted gene and regulatory
proteins recruited to these elements might be critical for
the modulation of the acetylation dependent NF-kB
response. Acetylation is known to be a reversible protein
modiﬁcation. In this regard HDAC-1, HDAC-2 and
HDAC-3 were reported to repress NF-kB-dependent
transcription upon treatment with inﬂammatory stimuli
(32,38,40). These histone deacetylases were also shown to
directly interact with several proteins involved in the
NF-kB signalling pathway, including NF-kB itself
(29,38,50). Deacetylation of RelA/p65 by HDAC-3 may
provide a counterpart mechanism for p300 function. The
exact molecular mechanism by which acetylation/deace-
tylation of RelA/p65 regulates the transcription activity of
RelA/p65 in the context of chromatin remains to be
investigated.
Together, acetylation of RelA/p65 presents an attractive
regulatory mechanism for the control of NF-kB-depen-
dent gene expression. The combination of acetylation with
other post-translational modiﬁcations will broaden even
more the potential of this regulation. Combinations of
diﬀerent modiﬁcations have already been proposed to
serve as a ‘code’ for the interacting domains of diﬀerent
proteins (51,52). Furthermore, acetylation can be regu-
lated by other post-translational modiﬁcations.
For example phosphorylation of RelA/p65 at serine 276
and 536 was shown to enhance the acetylation of lysine
310 (53). It cannot be excluded that other post-transla-
tional modiﬁcations of RelA/p65 can also regulate the
acetylation of this transcription factor. Our ﬁndings could
help to explain the diversity of NF-kB-dependent gene
expression upon diﬀerent stimuli. We hypothesize that
unique combinations of post-translational markers and
the presence of cell-type-speciﬁc cofactors determine the
speciﬁc NF-kB-mediated response. Recruitment analyses
of RelA/p65 to the promoter region of the regulated
genes using chromatin immunoprecipitation will help to
understand how post-translational modiﬁcations of this
transcription factor inﬂuence gene expression of its
target genes.
In conclusion, our results support the hypothesis that
p300-mediated acetylation of distinct sites in the RelA/p65
protein is important to modulate the expression of deﬁned
genes, thereby contributing to the speciﬁcity of the NF-kB
response.
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